The Pluses and Minuses of Innovation

Article

Applied Clinical Trials

Applied Clinical TrialsApplied Clinical Trials-08-01-2016
Volume 25
Issue 8

Survey delves deep into what constitutes true game-changing innovation in clinical development.

There is hype. And there is innovation. There are expectations and reality. While the chart below is from our latest survey conducted with SCORR Marketing on innovation, this question itself doesn’t use the “i” word. Something that has the “potential to change the future of clinical trials” should be considered an innovation, but of the five choices we gave, which is a true innovation? And does it matter if it indeed changes the future?  

The survey delved much deeper into what respondents think about innovation, what types of innovation is or is not being implemented, and how innovation is viewed by stakeholders. These results can be download for free here.

Other items of note from the survey include the majority of respondents feel that CROs are most accepting of innovative processes, while clinical sites are not; an equal number of companies have or don’t have an innovations department or infrastructure (43.4%); and the most often cited reason for hindering adoption of technological advances is cost. 


 

 

 

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
OM1 Sonja Wustrack
Related Content
© 2024 MJH Life Sciences

All rights reserved.